The decoding of the proteome is revolutionizing the way diseases are diagnosed, treated, and prevented. Biognosys invents and provides patented proteomics solutions at the quality, scale, and speed required to transform R&D, clinical trials, and clinical decision making.
Biognosys is the world leader in next-generation proteomics contract research services to support pharma and biotech research and clinical development.
We offer a complete suite of software solutions for any mass spectrometry proteomics application in industry or academic life sciences research.
Our kits and reagents for sample preparation, quantification and quality control empower researchers to apply cutting-edge proteomics in-house.
Spectronaut®, our flagship software for DIA proteomics analysis, recently turned 10! To celebrate this milestone and the release of Spectronaut 16, we are offering all new[...]READ MORE
Unprecedented progress in Artificial Intelligence (AI)-enhanced data analysis with Spectronaut® expedites the performance and affordability of TrueDiscovery™ proteomics[...]READ MORE
Spectronaut® 16 brings users the ability to identify and quantify more from their DIA data than ever[...]READ MORE
The expansion is part of the company’s growth strategy for North America and will foster collaboration with life science companies and[...]READ MORE
Highlights include the launch of Spectronaut® 16, which has undergone one of its most transformative upgrades to date, and innovations to Biognosys’ proprietary TrueTarget™[...]READ MORE
The appointment will support Biognosys’ transformation to a leading provider of protein insights for the development of new breakthrough[...]READ MORE
Biognosys’ leading discovery proteomics services to add depth to NeoGenomics’ multiomics solutions for biopharma clinical trials and[...]READ MORE
Data from Biognosys and its collaborators demonstrate the technological advances and utility of their proteomics platforms in oncology R&D and clinical[...]READ MORE
The TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms provide an integrated suite of research services that reveal deep biological insights from early stage[...]READ MORE
Biognosys’ TrueSignature™ proteomics panels serve as pharmacodynamic readout for protein degradation in Kymera’s discovery and clinical trial[...]READ MORE
The new and improved service will offer unprecedented depth, precision, and throughput, quantifying up to 3,000 proteins in plasma or[...]READ MORE
Access our knowledge base with relevant resources and guiding information.